Premier Alternatives

Cognito Therapeutics

Cambridge, MA · Founded 2016 · Privately Held (backing)

Developer of digital therapeutics designed to treat neurodegenerative disorders by modulating brain activity and targeting underlying disease mechanisms associated with cognitive decline. Cognito Therapeutics is based in Cambridge, MA and was founded in 2016. Its last reported valuation was $30 million in Jul 2016. It has raised $264 million across 2 recorded rounds; the latest was a $10.2 million early-stage round in Jun 2024.

Last reported valuation
$30.0M
Oct 2026
Priced at
—
Total raised
$264.4M
Last round
Early Stage VC
Jun 2024

Cognito Therapeutics key facts

as of Oct 2026
  • Developer of digital therapeutics designed to treat neurodegenerative disorders by modulating brain activity and targeting underlying disease mechanisms associated with cognitive decline.
  • Cognito Therapeutics is valued at approximately $30.0M as of Oct 2026 (last reported valuation).
  • It has raised $264.4M across 2 recorded rounds; the latest was Early Stage VC ($10.2M) in Jun 2024.
  • Notable investors include MicroVentures, Morningside Group, IAG Capital Partners, Wilson Sonsini Goodrich & Rosati, Starbloom Capital — 11 tracked in total.
  • Cognito Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently Jul 2024 ($10.2M sold to 3 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$30.0M

Cognito Therapeutics's last reported valuation, Jul 2016. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Cognito Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Cognito Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Cognito Therapeutics funding rounds

2 rounds
Jun 2024Early Stage VC$10.2MSEC filing▮
Jun 2022Later Stage VC$108.8MSEC filing▮
Full funding history →

Cognito Therapeutics valuation

Cognito Therapeutics's last reported valuation was $30 million in Jul 2016. No priced round, secondary trade or fund mark has surfaced since.

How much has Cognito Therapeutics raised?

Cognito Therapeutics has raised $264 million in total; 2 of its rounds are on record. The largest on record was a $109 million later-stage round in Jun 2022; the most recent was a $10.2 million early-stage round in Jun 2024.

Cognito Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently in Jul 2024 ($10.2 million sold to 3 investors).

Cognito Therapeutics investors

11 investors are on record for Cognito Therapeutics, including MicroVentures, Morningside Group, IAG Capital Partners and Wilson Sonsini Goodrich & Rosati. By type, the record holds 3 venture capital firms and 2 family offices. The early-stage round in Jun 2024 drew 3 investors.

About Cognito Therapeutics

Developer of digital therapeutics designed to treat neurodegenerative disorders by modulating brain activity and targeting underlying disease mechanisms associated with cognitive decline. The company offers therapies that induce specific brain wave oscillations through non-invasive stimulation, modulate neural activity, and activate immune responses in the brain to target amyloid plaques and tau tangles, enabling patients with neurodegenerative disorders to address disease progression and support cognitive function.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2016
Employees
42
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.